Skip to main content
CRS 2026 Annual Meeting & Exposition Main banner

Nanomedicine and Nanoscale Delivery (Focus Group – NND)

EGFRvIII peptide nanovaccine with chitosan and apoferritin carrier system: characterization and in vitro response

Camila Machado França de Almeida – PhD studant, USP - Universidade de São Paulo; Fabiana Testa Moura de Carvalho Vicentini – Principal Investigator (PI), USP - Universidade de São Paulo
Introduction:

This study involves the development of a nanovaccine for the treatment of melanoma, a type of cancer with a strong tendency for metastasis (1). The vaccine antigen is the EGFRvIII peptide, delivered by a system containing apoferritin and chitosan. Although peptide vaccines are generally safer, they show low immunogenicity, requiring adjuvant systems to support antigen recognition by antigen-presenting cells (APCs) (2). Thus, this study aims to characterize the quitosan-peptide-apoferrritin (QPA) nanovaccine and obtain initial evidence of its immunogenicity.

 

Learning Objectives:

  • Associate the adjuvant system influence with the nanovaccine in vitro response measured by ELISA
  • Detect evidence of peptide–adjuvant interaction in the characterization data
  • Understanding the process of obtaining the QPA nanovaccine